Iain MacPhee

TL;DR: Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation as discussed by the authors, however, individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose-adjusted trough concentrations of tacromin as compared with those who are CYP 3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations.

TL;DR: Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose‐adjusted trough concentrations of tacrolimus as compared with those who are CYP 3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations.

TL;DR: It is concluded that considerable advances in the different fields of tacrolimus monitoring have been achieved during this last decade, and the Expert Committee concludes that Continued efforts should focus on the opportunities to implement in clinical routine the combination of new standardized PK approaches with PG, and valid biomarkers to further personalize tacolimus therapy and to improve long-term outcomes for treated patients.

TL;DR: It is concluded that endogenous corticosterone release in rats with EAE plays an essential role in the spontaneous recovery that is observed in this condition, and the subsequent refractory phase that is characteristic of rats that have recovered from EAE induced by active immunization with MBP is not associated with chronically elevated cortic testosterone levels.

TL;DR: The CYP3AP1 genotype is a major factor in determining the dose requirement for tacrolimus, and genotyping may be of value in planning patient-specific drug dosing.